Literature DB >> 14566857

Multiple roles of the tuberous sclerosis complex genes.

Raymond S Yeung1.   

Abstract

Soon after proposing the "two-hit" hypothesis for tumorigenesis, Knudson pursued further experimental validation of the concept by using a rat model of dominantly inherited renal tumor. Today, the Eker rat is one of the best characterized models of tuberous sclerosis complex (TSC) and has been used extensively for study of the function of the TSC2 tumor suppressor gene. Along with TSC1, these two genes behave as expected for tumor suppressor genes with evidence for loss of heterozygosity in tumors and suppression of growth when expressed in proliferating cells. Despite much experimental work, the mechanisms of these genes have remained elusive until recently. This review summarizes some of the current concepts in our understanding of the biological and biochemical function of the TSC genes. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14566857     DOI: 10.1002/gcc.10256

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  12 in total

1.  Desmoplastic fibroma-like tumor of maxillofacial region associated with tuberous sclerosis.

Authors:  Roberto Vargas-Gonzalez; Walter San Martin-Brieke; Claudia Gil-Orduña; Fabiola Lara-Hernandez
Journal:  Pathol Oncol Res       Date:  2004-12-27       Impact factor: 3.201

2.  A defect in protein farnesylation suppresses a loss of Schizosaccharomyces pombe tsc2+, a homolog of the human gene predisposing to tuberous sclerosis complex.

Authors:  Yukiko Nakase; Keiko Fukuda; Yuji Chikashige; Chihiro Tsutsumi; Daisuke Morita; Shinpei Kawamoto; Mari Ohnuki; Yasushi Hiraoka; Tomohiro Matsumoto
Journal:  Genetics       Date:  2006-04-19       Impact factor: 4.562

3.  ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.

Authors:  Jennifer D Cohen; Jaime M C Gard; Raymond B Nagle; Justin D Dietrich; Terrence J Monks; Serrine S Lau
Journal:  Toxicol Sci       Date:  2011-08-02       Impact factor: 4.849

4.  mTORC2 is required for proliferation and survival of TSC2-null cells.

Authors:  Elena A Goncharova; Dmitry A Goncharov; Hua Li; Wittaya Pimtong; Stephen Lu; Irene Khavin; Vera P Krymskaya
Journal:  Mol Cell Biol       Date:  2011-04-11       Impact factor: 4.272

5.  Irradiation exacerbates cortical cytopathology in the Eker rat model of tuberous sclerosis complex, but does not induce hyperexcitability.

Authors:  Naranzogt Tschuluun; H Jürgen Wenzel; Philip A Schwartzkroin
Journal:  Epilepsy Res       Date:  2006-09-29       Impact factor: 3.045

6.  Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.

Authors:  Elena A Goncharova; Dmitriy A Goncharov; Matthew Spaits; Daniel J Noonan; Ekaterina Talovskaya; Andrew Eszterhas; Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2006-01-19       Impact factor: 6.914

Review 7.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

8.  Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN.

Authors:  Hisashi Hasumi; Masaya Baba; Yukiko Hasumi; Ying Huang; Hyoungbin Oh; Robert M Hughes; Mara E Klein; Shoichi Takikita; Kunio Nagashima; Laura S Schmidt; W Marston Linehan
Journal:  J Natl Cancer Inst       Date:  2012-11-12       Impact factor: 13.506

9.  SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.

Authors:  Alexey Tyryshkin; Abhisek Bhattacharya; N Tony Eissa
Journal:  Cancer Res       Date:  2014-04-01       Impact factor: 12.701

Review 10.  Crossing paths in Human Renal Cell Carcinoma (hRCC).

Authors:  Guadalupe Aparicio Gallego; Vanessa Medina Villaamil; Enrique Grande; Isabel Santamarina Caínzos; Luís M Antón Aparicio
Journal:  Int J Mol Sci       Date:  2012-10-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.